Why Hims & Hers Health stock moves
Hims & Hers Health rose sharply.
Written after the close on ·
Updated 02:00 with news that came after the close
Earnings report
Next report: November 9. On its last 15 report days Hims & Hers Health usually moved about 10.1%. On a normal day it moves 2.8%.
August 11, 2026: −3.97%May 12, 2026: −14.10%February 24, 2026: −0.32%November 4, 2025: −3.60%
Why today
16,415 news analyzed todayHims & Hers Health rose sharply.
Hims & Hers Health rose on Friday after it agreed to sell Eli Lilly's obesity drugs directly through its platform.
The S&P 500 rose only slightly over the same day, so the stock moved well apart from the market.
Over the last five trading days the stock fell slightly, while the S&P 500 fell sharply and its healthcare sector was roughly flat.
Investors are also looking ahead to the earnings report due Monday 9 November.
Today's move of +8.06% was 2.9 times a normal day's 2.8%. S&P 500 moved +0.31% on the same day.
Hims & Hers Health +8.06%S&P 500 +0.31%Much stronger than the market
What analysts expect, and how often they have been right
Analysts’ estimates for Hims & Hers Health.
Hims & Hers Health earned more than expected in 6 out of 8 reports.
For comparison, about 82% of reports from US companies beat the estimate in the last three years.
The share moved in the same direction as the earnings surprise in 3 out of 8 reports with a measured move, against about 55% of reports from US companies.
Ratings
Price targets
Latest price $26.00
Earnings against expectations, and the share’s reaction
Expected EPSAbove estimateBelow estimateAs expected$
Next reported quarter: expected earnings per share of $0.06 (November 9). For the current fiscal year, expected earnings per share changed from -$0.13 three months ago to -$0.56 now. 2026 estimate: -$0.56. 2027 estimate: $0.42.
Has the share price followed the business?
Price and earnings moved in the same direction: 2 out of 3 years. Across US companies, that happens in about 65% of years. In 2025, the price changed +34% and earnings per share −4%.
Revenue, profit and market cap
RevenueProfitMarket capHatched bars: analysts’ estimates.$B
Assets, liabilities and market cap
AssetsLiabilitiesMarket cap$B
Price and earnings moved in the same direction: 2 out of 3 years.Market cap (Now): $6.1BRevenue 2025: $2.3B
What the key figures say about Hims & Hers Health
The figures connect what Hims & Hers Health earns with what investors pay.
The line shows the share price in the same year, on its own scale. Hatched bars: analysts’ estimates.
Profit divided by the number of shares. Each share represents this much of the earnings.
2022–2025: -$0.32–$0.53. Peers: Lundbeck 3.92 DKK, Swedish Orphan Biovitrum 18.94 SEK. 2026 estimate: -$0.56 (-$0.91–-$0.01). 2027 estimate: $0.42 (-$0.09–$1.44).
What the company sold during the year.
2022–2025: $527M–$2.3B. Peers: Lundbeck 26.0 bn DKK, Swedish Orphan Biovitrum 32.0 bn SEK, Alvotech $495M. 2026 estimate: $3.2B ($3.2B–$3.3B). 2027 estimate: $4.0B ($3.7B–$4.6B).
The percentage of revenue left after the costs of running the business.
2022–2025: −13.0%–4.5%. Peers: Lundbeck 21.8%, Swedish Orphan Biovitrum 29.8%, Alvotech 9.7%.
Profit as a percentage of shareholders’ money in the company.
2022–2025: −21.1%–26.4%. Peers: Lundbeck 15.4%, Swedish Orphan Biovitrum 16.3%.
The price investors pay for each unit of annual earnings per share. Not shown for a loss.
2022–2025: 45.6–63.7. Peers: Lundbeck 14.3, Swedish Orphan Biovitrum 26.3. 2027 estimate: 62.0.
What investors pay for each unit the company sells.
2022–2025: 2.18–3.62. Peers: Lundbeck 2.14, Swedish Orphan Biovitrum 5.42. 2026 estimate: 1.89. 2027 estimate: 1.52.
Net debt divided by operating earnings before depreciation and amortisation.
2022–2025: -3.66–3.39. Peers: Lundbeck 0.87, Swedish Orphan Biovitrum 1.18, Alvotech 17.28.
More key figures
Market cap divided by shareholders’ equity, what remains after liabilities.
2022–2025: 4.29–13.64. Peers: Lundbeck 2.06, Swedish Orphan Biovitrum 3.82.
Market cap plus net debt, divided by operating earnings. This includes debt.
2022–2025: 75.0–81.6.
Cash left after investments, divided by the number of shares.
2022–2025: -$0.16–$0.90. Peers: Lundbeck 5.20 DKK, Swedish Orphan Biovitrum 18.69 SEK, Alvotech -$0.94.
The percentage of assets financed by shareholders’ equity.
2022–2025: 25.1%–85.1%.
What to watch next, and why
The earnings report shows how Hims & Hers Health's revenue and profit have changed.
- Earnings report
The earnings report shows how Hims & Hers Health's revenue and profit have changed.
Add to calendar
Earnings report
Next report: · Add to calendar · Google Calendar
On its last 15 report days Hims & Hers Health usually moved about 10.1%. On a normal day it moves 2.8%.
−3.97% −14.10% −0.32% −3.60%
$10,000 in Hims & Hers Health bought on September 13, 2019 is worth $26,500 today, with dividends reinvested.
The same amount in S&P 500 with dividends would have become $27,100.
What would $10,000 in Hims & Hers Health be worth today? →
What would $10,000 in Hims & Hers Health be worth today?
$26,500
with dividends reinvested, bought on September 13, 2019. The same amount in S&P 500 with dividends would have become $27,100.
At worst it was worth $3,170 (May 11, 2022).
The five biggest days of the journey
· +40.8% · the whole market rose 0.8% the same day
· −34.6% · the whole market rose 1.0% the same day
· +31.0% · the whole market rose 0.2% the same day · report day
· +27.7% · the whole market rose 1.0% the same day
· +27.7% · the whole market rose 0.1% the same day
Earlier days
−6.07% market −2.70% Hims & Hers Health fell slightly over the last five trading days. Read →
Hims & Hers Health fell slightly over the last five trading days.
The market fell sharply over the same days, so the stock moved more than the broader market.
Its sector was roughly flat.
The biggest driver was a deal with Eli Lilly announced after the last session, which lifted the shares on Friday.
−9.75% market −4.41% Hims & Hers Health fell sharply. Read →
Hims & Hers Health fell sharply.
Hims & Hers Health fell, moving well more than the market and its sector.
Its shares dropped while the S&P 500 fell very sharply, so the stock fell harder than the broader market.
Its sector ETF fell very sharply too, so the decline was broad but Hims & Hers Health still moved more than its peers.
Trading was well above its usual level, about double a normal session.
+3.74% market +1.65% Hims & Hers Health rose, within its usual daily range. Read →
Hims & Hers Health rose, within its usual daily range.
Hims & Hers Health moved more than the S&P 500, which rose sharply, and moved in line with its healthcare sector.
Likely drivers were the election result confirming Democratic control of Congress, which eased worries about drug pricing rules.
Analysts also said existing Medicare price negotiation rules will stay in place.
Over the last five trading days the stock fell clearly, while the healthcare sector rose very sharply.
+1.82% market +0.30% Hims & Hers Health rose without company news. Read →
Hims & Hers Health rose without company news.
It moved more than the S&P 500, which also rose slightly, but ran against a sector that fell slightly.
Over the last five trading days the shares fell clearly, while the S&P 500 fell clearly too and the Healthcare sector rose sharply.
The move was an ordinary one for the stock, and trading was around its usual level.
The next earnings report is due Monday 9 November 2026, which is likely to matter more for the shares than the recent daily swings.
Learn more · Why do stocks move on earnings day? · Why do stocks go up and down?